Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on Ophthalmopathy and Antibody Concentrations

Publisher： Karger

E-ISSN： 2235-0802|5|1|50-56

ISSN： 2235-0640

Source： European Thyroid Journal, Vol.5, Iss.1, 2016-02, pp. : 50-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Methylprednisolone Pulse Treatment of Graves' Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency

By  

European Thyroid Journal, Vol. 4, Iss. 4, 2015-0 ,pp. : 222-225

Karger

Access to resources Recommend Favorite

Treatment of Graves’ Disease in Children and Adolescents

By  

Hormone Research in Paediatrics, Vol. 49, Iss. 6, 1998-05 ,pp. : 255-257

Karger

Access to resources Recommend Favorite

Lack of Association between Selenium Status and Disease Severity and Activity in Patients with Graves' Ophthalmopathy

By  

European Thyroid Journal, Vol. 5, Iss. 1, 2016-01 ,pp. : 57-64

Karger

Access to resources Recommend Favorite

Platelet-Derived Growth Factor: A Key Factor in the Pathogenesis of Graves' Ophthalmopathy and Potential Target for Treatment

By  

European Thyroid Journal, Vol. 3, Iss. 4, 2014-12 ,pp. : 217-226

Karger

Access to resources Recommend Favorite

Radioiodine Treatment of Graves’ Disease in Young People

By  

Hormone Research in Paediatrics, Vol. 49, Iss. 6, 1998-05 ,pp. : 258-262

Karger

Access to resources Recommend Favorite